JP6100762B2 - 膜で被包されたナノ粒子および使用方法 - Google Patents

膜で被包されたナノ粒子および使用方法 Download PDF

Info

Publication number
JP6100762B2
JP6100762B2 JP2014513590A JP2014513590A JP6100762B2 JP 6100762 B2 JP6100762 B2 JP 6100762B2 JP 2014513590 A JP2014513590 A JP 2014513590A JP 2014513590 A JP2014513590 A JP 2014513590A JP 6100762 B2 JP6100762 B2 JP 6100762B2
Authority
JP
Japan
Prior art keywords
nanoparticles
membrane
cell
toxin
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014513590A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518200A (ja
JP2014518200A5 (OSRAM
Inventor
チャン，リャンファン
フー，チェ−ミン
ファン，ロニー，ホンボー
コップ，ジョナサン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California San Diego UCSD filed Critical University of California
Publication of JP2014518200A publication Critical patent/JP2014518200A/ja
Publication of JP2014518200A5 publication Critical patent/JP2014518200A5/ja
Application granted granted Critical
Publication of JP6100762B2 publication Critical patent/JP6100762B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
JP2014513590A 2011-06-02 2012-05-24 膜で被包されたナノ粒子および使用方法 Active JP6100762B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161492626P 2011-06-02 2011-06-02
US61/492,626 2011-06-02
PCT/US2012/039411 WO2013052167A2 (en) 2011-06-02 2012-05-24 Membrane encapsulated nanoparticles and method of use

Publications (3)

Publication Number Publication Date
JP2014518200A JP2014518200A (ja) 2014-07-28
JP2014518200A5 JP2014518200A5 (OSRAM) 2015-07-02
JP6100762B2 true JP6100762B2 (ja) 2017-03-22

Family

ID=48044349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014513590A Active JP6100762B2 (ja) 2011-06-02 2012-05-24 膜で被包されたナノ粒子および使用方法

Country Status (9)

Country Link
US (5) US12097290B2 (OSRAM)
EP (2) EP3412282B1 (OSRAM)
JP (1) JP6100762B2 (OSRAM)
CN (2) CN103857387B (OSRAM)
CA (1) CA2873404C (OSRAM)
DK (1) DK2714017T3 (OSRAM)
ES (1) ES2685333T3 (OSRAM)
TW (2) TWI668019B (OSRAM)
WO (1) WO2013052167A2 (OSRAM)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP3412282B1 (en) 2011-06-02 2024-10-09 The Regents of the University of California Membrane encapsulated nanoparticles and method of use
WO2012174173A2 (en) * 2011-06-13 2012-12-20 President And Fellows Of Harvard College Multi-color nanoscale imaging based on nanoparticle cathodoluminescence
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9702795B2 (en) * 2012-01-17 2017-07-11 The Scripps Research Institute Apparatus and method for producing specimens for electron microscopy
WO2013109405A1 (en) * 2012-01-17 2013-07-25 The Scripps Research Institute Preparation of specimen arrays on an em grid
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6450673B2 (ja) * 2012-04-03 2019-01-09 リニューロン・リミテッドＲｅＮｅｕｒｏｎ Ｌｉｍｉｔｅｄ 幹細胞微粒子
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10954489B2 (en) 2013-06-04 2021-03-23 The Regents Of The University Of California Liver-mimetic device and method for simulation of hepatic function using such device
WO2015021390A2 (en) * 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
WO2015084677A1 (en) 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
US10098839B2 (en) 2014-03-20 2018-10-16 The Regents Of The University Of California Hydrogel toxin-absorbing or binding nanoparticles
PT3981437T (pt) 2014-04-23 2025-01-15 Modernatx Inc Vacinas de ácidos nucleicos
US10117886B2 (en) 2014-05-30 2018-11-06 Hao Cheng Hyaluronidase and a low density second PEG layer on the surface of therapeutic-encapsulated nanoparticles to enhance nanoparticle diffusion and circulation
WO2015187502A1 (en) * 2014-06-02 2015-12-10 Cellics Therapeutics, Inc. Use of nanoparticles coated with red blood cell membranes to treat hemolytic diseases and disorders
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
US12285472B2 (en) * 2014-08-20 2025-04-29 The Regents Of The University Of California Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof
WO2016044483A1 (en) 2014-09-16 2016-03-24 The Regents Of The University Of California Method for fabrication of microwells for controlled formation of 3-dimensional multicellular-shapes
US9623081B2 (en) 2014-10-03 2017-04-18 Ntercept, Llc Compositions and methods for inhibiting the biological activity of soluble biomolecules
WO2016109306A1 (en) * 2015-01-02 2016-07-07 Cellics Therapeutics, Inc. Use of nanoparticles coated with red blood cell membranes to enable blood transfusion
KR101720851B1 (ko) * 2015-01-29 2017-03-28 포항공과대학교 산학협력단 세포의 지질막에서 유래된 나노소포체 및 이의 용도
CN107530291A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 双重负载的脂质体药物制剂
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
WO2016153979A1 (en) * 2015-03-20 2016-09-29 The Regents Of The University Of California Modulating antibacterial immunity via bacterial membrane-coated nanoparticles
CN107847442B (zh) * 2015-04-20 2021-03-16 中央研究院 类血小板蛋白微粒及利用类血小板蛋白微粒传递药物的方法
US10610493B2 (en) 2015-04-29 2020-04-07 The Regents Of The University Of California Detoxification using nanoparticles
CN104922671B (zh) * 2015-06-09 2017-12-08 深圳先进技术研究院 一种吲哚菁绿复合纳米颗粒及其制备方法和应用
MA45481A (fr) * 2015-06-10 2018-04-18 Univ Texas Utilisation d'exosomes pour le traitement de maladies
US11224577B2 (en) 2015-06-19 2022-01-18 The Regents Of The University Of California Treating infection by a platelet-targeting microbe using nanoparticles
WO2016205010A1 (en) * 2015-06-19 2016-12-22 The Regents Of The University Of California Treating vasculature related diseases or disorders using nanoparticles
EP3316864A4 (en) * 2015-06-30 2019-03-06 Nanotics, LLC COMPOSITIONS AND METHODS RELATED TO SCAVENGER PARTICLES
WO2017008016A1 (en) * 2015-07-09 2017-01-12 The Board Of Regents Of The University Of Texas System Nanoparticles containing extracellular matrix for drug delivery
TW201718638A (zh) 2015-07-21 2017-06-01 現代治療公司 傳染病疫苗
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017027760A1 (en) * 2015-08-12 2017-02-16 North Carolina State University Platelet membrane-coated drug delivery system
WO2017030929A1 (en) * 2015-08-14 2017-02-23 The Johns Hopkins University Decoy nanoparticles to disrupt cancer cell-stormal cell networks
SMT202200178T1 (it) 2015-09-17 2022-05-12 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti terapeutici
MA45209A (fr) 2015-10-22 2019-04-17 Modernatx Inc Vaccins contre les maladies sexuellement transmissibles
EP3718565B1 (en) 2015-10-22 2022-04-27 ModernaTX, Inc. Respiratory virus vaccines
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
US11643441B1 (en) 2015-10-22 2023-05-09 Modernatx, Inc. Nucleic acid vaccines for varicella zoster virus (VZV)
US11359058B2 (en) 2015-11-18 2022-06-14 Arytha Biosciences, Llc Processes and systems for preparing cellular or viral membranes and nanoparticles
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
PL3394030T3 (pl) 2015-12-22 2022-04-11 Modernatx, Inc. Związki i kompozycje do wewnątrzkomórkowego dostarczania środków
SI3394093T1 (sl) 2015-12-23 2022-05-31 Modernatx, Inc. Metode uporabe liganda OX40, ki kodira polinukleotid
WO2017117275A1 (en) * 2015-12-31 2017-07-06 City Of Hope Silica nanoparticle with platinum anti-cancer agent
US11000593B2 (en) 2016-01-08 2021-05-11 The Regents Of The University Of California Cellular or viral membrane coated nanostructures and uses thereof
MA43587A (fr) 2016-01-10 2018-11-14 Modernatx Inc Arnm thérapeutiques codant pour des anticorps anti-ctla-4
CN105497912A (zh) * 2016-01-21 2016-04-20 华东师范大学 红细胞膜包裹的酸敏感高分子前药纳米递药系统的制备方法及用途
CN105769818B (zh) * 2016-03-16 2019-03-01 华东师范大学 用于抗体药物递送的红细胞膜包裹的抗体纳米粒子及制备方法
US20200289666A1 (en) * 2016-03-28 2020-09-17 The Johns Hopkins University Biomimetic anisotropic polymeric particles with naturally derived cell membranes for enhanced drug delivery
CN106362148B (zh) * 2016-09-12 2019-08-27 中南大学 一种普鲁士蓝纳米介晶细胞膜包覆修饰方法
CN110035742A (zh) * 2016-09-29 2019-07-19 北卡罗来纳州立大学 干细胞仿生微粒
WO2018085407A1 (en) * 2016-11-02 2018-05-11 Nanoproteagen Polymeric nanoparticles
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
CN106620684A (zh) * 2016-11-18 2017-05-10 上海交通大学医学院附属新华医院 一种泛耐药菌的纳米疫苗及其制备方法
US11103578B2 (en) 2016-12-08 2021-08-31 Modernatx, Inc. Respiratory virus nucleic acid vaccines
JP2020504177A (ja) 2017-01-04 2020-02-06 ナノティックス，エルエルシー 捕捉粒子をアセンブルするための方法
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
LT3596041T (lt) 2017-03-15 2023-01-25 Modernatx, Inc. Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys
AU2018234814B2 (en) 2017-03-15 2022-06-30 Modernatx, Inc. Crystal forms of amino lipids
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
CN108653236B (zh) 2017-03-31 2025-03-25 上海惠永药物研究有限公司 一种生物膜包载药物纳米晶体的制备方法及其用途
US11413252B2 (en) * 2017-04-21 2022-08-16 Coastar Therapeutics Inc. Membrane lipid coated viral nanoparticles and method of use
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
WO2019022671A1 (en) * 2017-07-28 2019-01-31 National University Of Singapore BIOMOLECULAR COMPOSITES COMPRISING MODIFIED CELLULAR PHANTOMS
CN111315359A (zh) 2017-08-31 2020-06-19 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
US20210187018A1 (en) * 2017-12-07 2021-06-24 Flagship Pioneering Innovations V, Inc. Cytobiologics and therapeutic uses thereof
CN108066317B (zh) * 2017-12-19 2020-04-03 中南大学湘雅三医院 纳米药物控释体系的制备方法及其产品与应用
WO2019143637A1 (en) 2018-01-18 2019-07-25 Cellics Therapeutics, Inc. Methods and compositions for quantifying hemoglobin
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
CN108042510A (zh) * 2018-02-11 2018-05-18 复旦大学附属中山医院 一种靶向动脉粥样硬化斑块的血小板膜包被的雷帕霉素仿生纳米颗粒及其用途
US10842755B2 (en) 2018-03-23 2020-11-24 University Of South Carolina Nanoparticles for brain targeted drug delivery
EP3773520A4 (en) 2018-04-09 2021-12-22 Orgenesis Inc. BIOXOMES AND REDOXOMES PARTICLES, PROCESS AND COMPOSITION
CN108498805B (zh) * 2018-04-20 2021-04-09 中国科学院化学研究所 一种利用生物细胞膜提高阳离子共轭聚合物生物相容性的方法
US12478588B2 (en) 2018-05-25 2025-11-25 The Penn State Research Foundation Nanoparticle for protein delivery
WO2019246014A1 (en) * 2018-06-18 2019-12-26 North Carolina State University Stem cell biomimetic nanoparticle therapeutic agents and uses thereof
KR20210043574A (ko) 2018-07-09 2021-04-21 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 푸소좀 조성물 및 이의 용도
WO2020023436A1 (en) * 2018-07-23 2020-01-30 Campbell Robert B Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy
US11096899B2 (en) * 2018-09-07 2021-08-24 Wisconsin Alumni Research Foundation Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment
CA3113436A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
AU2019345067A1 (en) 2018-09-19 2021-04-08 Modernatx, Inc. High-purity peg lipids and uses thereof
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020080876A1 (ko) * 2018-10-18 2020-04-23 고려대학교 세종산학협력단 생체 물질 검출 센서 및 그 제조방법
CN113631718A (zh) 2018-11-14 2021-11-09 旗舰先锋创新V股份有限公司 用于特定隔室货物递送的组合物和方法
WO2020105048A1 (en) * 2018-11-22 2020-05-28 Ramot At Tel-Aviv University Ltd. Immunogenic compositions containing n-glycolylneuraminic acid bearing nanoparticles
CN111214439B (zh) * 2018-11-23 2023-02-10 复旦大学 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途
EP3886870A4 (en) * 2018-11-26 2022-10-12 Arytha Biosciences LLC Nanoparticles containing cellular membrane and uses thereof
WO2020113059A1 (en) * 2018-11-28 2020-06-04 Papoutsakis Eleftherios T Biomembrane-covered nanoparticles (bionps) for delivering active agents to stem cells
US10265017B1 (en) * 2018-12-12 2019-04-23 Lucas J. Myslinski Device, method and system for implementing a physical area network for cancer immunotherapy
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
MX2021010273A (es) 2019-02-27 2021-09-23 Actym Therapeutics Inc Bacterias inmunoestimuladoras modificadas para colonizar tumores, celulas inmunitarias residentes de tumor y el microentorno tumoral.
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
US20220221464A1 (en) * 2019-04-30 2022-07-14 The Regents Of The University Of California Broad-Spectrum Nanoparticle Enabled Genomic Detection
CN111956947A (zh) * 2019-05-20 2020-11-20 安行生物技术有限公司 向细胞内递送纳米颗粒的方法和装置
EP3979994A4 (en) * 2019-06-07 2023-08-09 President And Fellows Of Harvard College Compositions and methods relating to erythrocytes with adhered particles
CN110179769A (zh) * 2019-06-11 2019-08-30 北京大学深圳医院 一种可以诱导病灶部位局部免疫应答的微纳米粒子药物载体
CN110269847A (zh) * 2019-06-21 2019-09-24 温州医科大学 一种用于中和细菌毒素的仿生纳米材料及其制备方法与应用
CN110302369B (zh) * 2019-06-28 2022-04-29 中国人民解放军陆军军医大学 以壳聚糖修饰PLGA的大肠杆菌Vo外膜蛋白纳米粒疫苗及其制备方法和应用
CN114144198A (zh) * 2019-07-16 2022-03-04 科斯塔治疗公司 膜脂包覆的纳米颗粒的制备方法
US20220331365A1 (en) * 2019-09-03 2022-10-20 The Regents Of The University Of California Biomimetic nanoemulsions for oxygen delivery
EP4031582A4 (en) * 2019-09-18 2023-10-04 The Regents of the University of California IMMUNOACTIVE MICROPARTICLES AND ASSOCIATED USES
BR112022004759A2 (pt) 2019-09-19 2022-06-21 Modernatx Inc Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
WO2021091582A1 (en) * 2019-11-08 2021-05-14 The Methodist Hospital Neurosome/astrosome compositions and methods of use
US11771650B2 (en) * 2019-12-20 2023-10-03 Mcmaster University Hybrid biological membranes, methods of making and uses thereof
CN113041345B (zh) * 2019-12-26 2023-09-01 复旦大学 一种纳米类毒素疫苗及其用途
CN111111480B (zh) * 2020-01-09 2021-09-14 南京工业大学 一种唑来磷酸改性纳滤膜及其制备方法
WO2021150460A1 (en) * 2020-01-20 2021-07-29 Arytha Biosciences Llc Devices containing cellular membrane and uses thereof
US20230083448A1 (en) * 2020-02-07 2023-03-16 The Johns Hopkins University Compositions of alum nanoparticles for immunomodulation and methods for producing the same
WO2021163455A1 (en) * 2020-02-14 2021-08-19 The Trustees Of Columbia University In The City Of New York Scalable and facile cell-membrane-coating technology for both positively and negatively charged particles
CN111265549B (zh) * 2020-03-02 2022-03-01 苏州大学 表面pd-l1分子过表达的间充质干细胞膜包被的仿生纳米颗粒及其制备和应用
WO2021194938A1 (en) * 2020-03-24 2021-09-30 The Regents Of The University Of California Universal nanosponge for treating respiratory viral infection
CN113679829B (zh) * 2020-05-18 2024-01-02 北京繁易纳维科技有限公司 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用
CN111603454A (zh) * 2020-06-08 2020-09-01 上海交通大学医学院附属第九人民医院 一种多重靶向的融合细胞膜修饰的仿生纳米递送系统及其制备方法与应用
WO2022020985A1 (zh) * 2020-07-27 2022-02-03 上海市公共卫生临床中心 利用呼吸道上皮细胞膜防治呼吸道传染病的方法及应用
CN113041356B (zh) * 2020-10-28 2022-07-22 湖南中医药大学 血筒素靶向载药体系、制备方法及其应用
US20250009678A1 (en) * 2020-12-07 2025-01-09 Fortuga Bio Dendritic cell-mimicked nanostructure for application to cancer immunotherapy, and fabrication method therefor
US12041939B2 (en) 2020-12-08 2024-07-23 Cornell University Enzyme-loaded pollen-mimicking microparticles for organophosphate detoxification of insect pollinators
CN112730324B (zh) * 2020-12-17 2022-11-08 中山大学 基于量子点掺杂的pla纳米线共振散射折射率传感器
CN114762726A (zh) * 2021-01-15 2022-07-19 上海交通大学医学院附属仁济医院 抗原递呈细胞膜包裹的纳米颗粒及制备方法与应用
CN113209044A (zh) * 2021-01-29 2021-08-06 广州医科大学 靶向递送HDACIs的仿生纳米颗粒及其制备方法和应用
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CN113244189A (zh) * 2021-02-22 2021-08-13 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 一种基于红细胞膜的超小仿生纳米颗粒制备方法
JP2024514196A (ja) * 2021-04-13 2024-03-28 マクマスター・ユニバーシティ 改変型タンパク質分子を含む機能化された生体膜、並びにその作成方法及び使用
CN113181354B (zh) * 2021-04-25 2023-05-26 中国农业科学院兰州兽医研究所 基于树突状细胞的口蹄疫仿生纳米疫苗及其制备方法和应用
CN113133988B (zh) * 2021-04-26 2023-04-07 西南医科大学附属医院 一种红细胞膜仿生修饰的肾靶向纳米载药系统、制备方法及应用
CN113197880B (zh) * 2021-05-07 2021-11-12 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种巨噬细胞外泌体膜包被仿生纳米颗粒及其制备方法和应用
CN113633625B (zh) * 2021-05-19 2022-12-09 河南大学 一种杂膜负载氧化磷酸化抑制剂的纳米药物及其制备方法
CN113398900B (zh) * 2021-07-14 2023-03-31 广州汇标检测技术中心 一种针对黄曲霉毒素的分子印迹材料及其制备方法和应用
US20230032473A1 (en) * 2021-07-23 2023-02-02 Wisconsin Alumni Research Foundation Nad(h) nanoparticles and methods of use
CN113893229B (zh) * 2021-08-06 2023-09-05 四川省医学科学院·四川省人民医院 一种红细胞膜包裹藤黄酸的仿生纳米颗粒、制备方法及其应用
CN113925836A (zh) * 2021-09-29 2022-01-14 苏州大学 清除rankl的细胞膜包被纳米诱饵、其制备及应用
CN114129536A (zh) * 2021-12-03 2022-03-04 深圳市融创金石科技有限公司 仿生普鲁士蓝复合材料及其制备方法和应用
CN114470223B (zh) * 2022-01-13 2023-09-29 苏州大学 清除促炎因子和抑制t细胞活化的细胞膜包被纳米诱饵及其制备方法与应用
WO2023153832A1 (ko) * 2022-02-14 2023-08-17 가천대학교 산학협력단 병소에 대한 표적능이 강화된 엑토좀-생분해성 고분자 나노입자 복합체 및 그의 제조방법
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
CN114668772B (zh) * 2022-03-15 2024-12-10 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 负载两性霉素b仿生纳米系统的组合物、制备方法及应用
WO2023220067A1 (en) * 2022-05-09 2023-11-16 Yale University Immunotherapy of skin cancer using mpla-loaded hpg nanoparticles
CN115068606B (zh) * 2022-05-23 2023-05-16 山东大学 一种肿瘤靶向纳米制剂、制备方法及在抗肿瘤药物制备中的应用
CN115227671B (zh) * 2022-07-13 2024-01-19 中山大学附属第一医院 一种药物递送系统及其制备方法和应用
CN115590836B (zh) * 2022-09-27 2024-06-21 浙江大学 一种提高mRNA疫苗诱导免疫应答能力的脂质纳米颗粒及其应用
CN116139104A (zh) * 2022-11-29 2023-05-23 深圳先进技术研究院 一种靶向性仿生聚多肽纳米递送载体、纳米核酸递送系统及其制备方法和应用
CN115804762B (zh) * 2022-12-20 2024-05-31 浙江大学 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用
CN116270525B (zh) * 2023-02-22 2024-12-13 南京华盖制药有限公司 一种用于治疗肺部细菌感染性肺炎的可吸入仿生纳米材料及其制备方法和应用
CN118717701A (zh) * 2023-03-29 2024-10-01 国家纳米科学中心 细菌矿化金属纳米颗粒用于治疗肿瘤
WO2024249782A2 (en) * 2023-06-02 2024-12-05 The Methodist Hospital Biomimetic proteolipid nanovesicles for delivery of nucleic acids
CN116531344A (zh) * 2023-06-07 2023-08-04 重庆医科大学附属儿童医院 一种巨噬细胞膜修饰的纳米颗粒及其制备方法和应用
KR20250000043A (ko) * 2023-06-23 2025-01-02 한양대학교 산학협력단 나노입자, 이의 제조 방법 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CN116652180B (zh) * 2023-07-31 2023-09-26 环保桥(湖南)生态环境工程股份有限公司 一种基于零价铁粉的复合颗粒及其制备方法与应用
EP4520345A1 (en) 2023-09-06 2025-03-12 Myneo Nv Product
EP4556028A1 (en) 2023-11-14 2025-05-21 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie - Hans-Knöll-Institut - Functionalized nanoparticles for viral clearance

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59157033A (ja) * 1983-02-28 1984-09-06 Hidetoshi Tsuchida 赤血球ゴ−スト膜フラグメントからなる小胞体の製造方法および小胞体
US4891208A (en) 1985-04-10 1990-01-02 The Liposome Company, Inc. Steroidal liposomes
US5304382A (en) * 1989-08-18 1994-04-19 Monsanto Company Ferritin analogs
JPH05506233A (ja) * 1990-04-24 1993-09-16 フラスタット・ピーティーワイ・リミテッド 赤血球の表面に結合した抗原を含むワクチン
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5491219A (en) * 1993-06-11 1996-02-13 Protein Magnetics Ferritin with ferrimagnetically ordered ferrite core and method technical field
CA2150617C (en) * 1995-02-07 2001-10-30 Universite Laval Nanoerythrosome as bioactive agent carrier
CA2213906A1 (en) * 1996-09-23 1998-03-23 Dusica Maysinger Pharmaceutical composition and method for neuron rescue in ischemic stroke
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
FR2839260B1 (fr) * 2002-05-03 2005-02-25 Inst Nat Sante Rech Med Microparticules a base d'un materiau bicompatible et biodegradable, supportant des cellules et des substances biologiquement actives
US20040180094A1 (en) * 2003-03-11 2004-09-16 Hemolytics, Inc. Activation agents on the surface of encapsulation vesicles
ATE437633T2 (de) 2003-06-02 2009-08-15 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
EP1773303A2 (en) * 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
WO2008048288A2 (en) * 2005-11-09 2008-04-24 Montana State University Novel nanoparticles and use thereof
WO2007113222A2 (en) 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
US20070243137A1 (en) * 2006-04-18 2007-10-18 Nanoprobes, Inc. Cell and sub-cell methods for imaging and therapy
GB2439747A (en) 2006-07-03 2008-01-09 Uni Degli Studi Di Urbino Carl Delivery of contrasting agents for magnetic resonance imaging
WO2008013952A2 (en) * 2006-07-27 2008-01-31 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
WO2008150276A2 (en) * 2006-09-26 2008-12-11 The Board Of Regents Of The University Of Texas System Virus coated nanoparticles and uses thereof
RU2345805C1 (ru) 2007-07-04 2009-02-10 Государственное образовательное учреждение высшего профессионального образования "Саратовский государственный университет им. Н.Г. Чернышевского" Способ лазерного фототермолиза серповидно-клеточных эритроцитов
US8329161B2 (en) * 2008-05-01 2012-12-11 National Health Research Institutes Red blood cell-derived vesicles as a nanoparticle drug delivery system
CN102170903B (zh) 2008-05-02 2016-04-06 亮点医疗有限公司 用于刺激免疫反应的产品和方法
CN101306196B (zh) 2008-07-03 2011-05-11 中国科学院长春应用化学研究所 一种生物降解的键合了血红蛋白分子的纳米粒子及制法
WO2010070620A1 (en) * 2008-12-21 2010-06-24 Consiglio Nazionale Delle Ricerche Erythrocyte-based delivery system, method of preparation and uses thereof
JP5667180B2 (ja) * 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
CN101735613B (zh) 2009-12-08 2012-09-05 四川大学 一种聚合物多孔纳米微球及其制备方法
WO2011116237A1 (en) * 2010-03-17 2011-09-22 Board Of Regents Of The University Of Texas System Universal cell-directed theranostics
NO2575876T3 (OSRAM) * 2010-05-26 2018-05-05
GB201011968D0 (en) 2010-07-16 2010-09-01 Secr Defence Toxoiding method
CN101926984B (zh) * 2010-08-05 2012-09-05 中国人民解放军第四军医大学 一种人工纳米红细胞的制备方法
CN101934080B (zh) * 2010-09-08 2012-05-23 西北大学 一种利用静电自组装涂层改善材料血液相容性的方法
JP2014512409A (ja) * 2011-04-28 2014-05-22 エスティーシー． ユーエヌエム 標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその使用方法
EP3412282B1 (en) 2011-06-02 2024-10-09 The Regents of the University of California Membrane encapsulated nanoparticles and method of use
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
WO2015084677A1 (en) 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
US10098839B2 (en) 2014-03-20 2018-10-16 The Regents Of The University Of California Hydrogel toxin-absorbing or binding nanoparticles
WO2015187502A1 (en) 2014-06-02 2015-12-10 Cellics Therapeutics, Inc. Use of nanoparticles coated with red blood cell membranes to treat hemolytic diseases and disorders
US12285472B2 (en) * 2014-08-20 2025-04-29 The Regents Of The University Of California Self-antigen displaying nanoparticles targeting auto-reactive immune factors and uses thereof
WO2016109306A1 (en) 2015-01-02 2016-07-07 Cellics Therapeutics, Inc. Use of nanoparticles coated with red blood cell membranes to enable blood transfusion
WO2016153979A1 (en) * 2015-03-20 2016-09-29 The Regents Of The University Of California Modulating antibacterial immunity via bacterial membrane-coated nanoparticles
US10610493B2 (en) 2015-04-29 2020-04-07 The Regents Of The University Of California Detoxification using nanoparticles
US11224577B2 (en) 2015-06-19 2022-01-18 The Regents Of The University Of California Treating infection by a platelet-targeting microbe using nanoparticles
WO2016205010A1 (en) 2015-06-19 2016-12-22 The Regents Of The University Of California Treating vasculature related diseases or disorders using nanoparticles
US11359058B2 (en) * 2015-11-18 2022-06-14 Arytha Biosciences, Llc Processes and systems for preparing cellular or viral membranes and nanoparticles
US11000593B2 (en) * 2016-01-08 2021-05-11 The Regents Of The University Of California Cellular or viral membrane coated nanostructures and uses thereof

Also Published As

Publication number Publication date
TW201311297A (zh) 2013-03-16
CN103857387B (zh) 2017-03-15
EP3412282C0 (en) 2024-10-09
EP2714017A4 (en) 2015-06-03
TWI668019B (zh) 2019-08-11
JP2014518200A (ja) 2014-07-28
WO2013052167A2 (en) 2013-04-11
US20250049716A1 (en) 2025-02-13
WO2013052167A3 (en) 2014-05-01
CN103857387A (zh) 2014-06-11
DK2714017T3 (en) 2018-09-03
EP3412282A1 (en) 2018-12-12
ES2685333T3 (es) 2018-10-08
EP2714017A2 (en) 2014-04-09
US20250017860A1 (en) 2025-01-16
CN107115314A (zh) 2017-09-01
US20250049715A1 (en) 2025-02-13
US20240252438A1 (en) 2024-08-01
EP3412282B1 (en) 2024-10-09
TWI638667B (zh) 2018-10-21
TW201729799A (zh) 2017-09-01
US12097290B2 (en) 2024-09-24
CN107115314B (zh) 2022-04-29
CA2873404A1 (en) 2013-04-11
HK1197016A1 (en) 2015-01-02
EP2714017B1 (en) 2018-08-01
CA2873404C (en) 2022-08-30
US20130337066A1 (en) 2013-12-19
HK1243002A1 (zh) 2018-07-06

Similar Documents

Publication Publication Date Title
JP6100762B2 (ja) 膜で被包されたナノ粒子および使用方法
Feng et al. Immunomodulatory nanosystems
Jahromi et al. Chemically engineered immune cell‐derived microrobots and biomimetic nanoparticles: emerging biodiagnostic and therapeutic tools
Kim et al. Nanosac, a noncationic and soft polyphenol nanocapsule, enables systemic delivery of siRNA to solid tumors
Zhu et al. Applications of nanomaterials as vaccine adjuvants
Liang et al. Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development
Ferber et al. Immunology‐guided biomaterial design for mucosal cancer vaccines
US10117886B2 (en) Hyaluronidase and a low density second PEG layer on the surface of therapeutic-encapsulated nanoparticles to enhance nanoparticle diffusion and circulation
Abdel‐Bar et al. Combinatory delivery of etoposide and siCD47 in a lipid polymer hybrid delays lung tumor growth in an experimental melanoma lung metastatic model
EP4069305A1 (en) Nanostructured drug delivery system as a multifunctional platform for therapy
Yan et al. Cell membrane-camouflaged PLGA biomimetic system for diverse biomedical application
CN113646003A (zh) 多配体官能化的聚合物泡囊
Longobardi et al. Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy
Tanwar et al. Nanoparticles: Scope in drug delivery
HK1243002B (en) Membrane encapsulated nanoparticles and method of use
HK40001508A (en) Membrane encapsulated nanoparticles and method of use
Mandal Design, development and evaluation of erlotinib-loaded hybrid nanoparticles for targeted drug delivery to non-small cell lung cancer
Dion et al. Engineering Immunity to Disease Using Nanotechnology
HK1197016B (en) Membrane encapsulated nanoparticles and method of use
Thamphiwatana Antimicrobial Nanotherapeutics Against Helicobacter pylori Infection
Ferreira et al. 3.5 Current Trends and Developments for Nanotechnology in Cancer
Kroll Cell Membrane-Coated Nanoparticles for Immune Modulation
Yanasarn Lipid Based Nanocarriers for Chemotherapeutic Drug Docetaxel and Vaccine Delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160817

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170223

R150 Certificate of patent or registration of utility model

Ref document number: 6100762

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250